<DOC>
	<DOC>NCT01218477</DOC>
	<brief_summary>The purpose of the study is to determine the safety and tolerability of the combination of BMS-833923 plus dasatinib in patients with chronic myeloid leukemia.</brief_summary>
	<brief_title>Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Key Inclusion Criteria Age ≥18 years Diagnosis of chronic myeloid leukemia (CML) and cytogenetic positive for the Philadelphia chromosome (Ph+), documented Ph+ cells on bone marrow assessment (BMA) ≤6 weeks prior to treatment Either chronicphase CML, with &lt;15% blasts in peripheral blood and bone marrow, or advancedphase CML, including Ph+ acute lymphoblastic leukemia (ALL) (&gt; 5% blasts) or hematologic progression with ≥15% blasts not in complete cytogenetic remission Resistance or suboptimal response to imatinib, dasatinib, or nilotinib and no known T315I/A Ablkinase mutation. Key Exclusion Criteria Known Ablkinase T315I or T315A mutation CCyR at baseline Any serious or uncontrolled medical disorder or active infection that would impair the ability of the subject to receive protocol therapy Uncontrolled or significant cardiovascular disease Grade 3 or higher peripheral blood counts Serum calcium or phosphate below the lower limit of normal Baseline hypomagnesemia and amylase or lipase at least Grade 1 or higher Reduced renal function, defined as serum creatinine level &gt;3*upper limit of normal Prior therapies for CML or Ph+ ALL permitted, with the following restriction: Therapy permitted with corticosteroids, hydroxyurea, or anagrelide prior to starting treatment and during the first 4 weeks on study 6 months or longer after stem cell transplantation 28 days or longer after any investigational agent 7 days or longer after any standard chemotherapy agent Concomitant use of medications with a known risk of causing Torsades de Pointes Concomitant use of strong inhibitors of the CYP3A4 isoenzyme</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>(Chronic Myeloid Leukemia-Chronic Phase and Advanced)</keyword>
</DOC>